University of Cologne Researchers Identify cFLIP Protein as Critical Vulnerability in Aggressive ABC-DLBCL Lymphoma

University of Cologne researchers find cFLIP protein blocks cell death in aggressive DLBCL, revealing a new target for therapy-resistant blood cancer.

By: AXL Media

Published: Apr 25, 2026, 8:26 AM EDT

Source: Information for this report was sourced from EurekAlert!

Breaching the Defenses of Aggressive Blood Cancer

Medical researchers at the University of Cologne have identified a molecular mechanism that allows aggressive lymphoma cells to achieve a form of biological immortality. In a study published in the journal Blood, the team detailed how Diffuse Large B Cell Lymphoma, or DLBCL, utilizes specific proteins to block programmed cell death, known as apoptosis. While modern treatments currently cure about 60 percent of patients, the remaining 50 percent of those who relapse face a lack of effective options. According to Dr. Alessandro Annibaldi, lead investigator at the Center for Molecular Medicine Cologne, identifying these cellular roadblocks is essential for re-programming the fate of cancer cells and forcing them toward a natural death cycle.

The Duel Between Intrinsic and Extrinsic Apoptosis

The survival strategy of DLBCL cells involves a dual-layered defense system that protects them from both internal and external triggers for cell death. Typically, these cancer cells overexpress the BCL2 protein, which guards the intrinsic arm of apoptosis, essentially preventing the cell from destroying itself from within. However, the Cologne research team discovered that the cells also overexpress a second protein called cFLIP. By securing both the intrinsic and extrinsic avenues of cell death, the lymphoma cells gain a significant survival advantage over healthy cells. This redundant protection system is what makes the ABC-DLBCL subtype particularly resistant to standard therapies and difficult to treat successfully.

Mapping the Roadblocks to Cancer Cell Immortality

To uncover these vulnerabilities, the research group utilized sophisticated molecular biology techniques and preclinical models. They successfully demonstrated that by removing the cFLIP protein, they could dismantle the roadblock on the extrinsic cell death pathway. Dr. Annibaldi noted that while the existence of such a secondary defense had been theorized for years, his group was the first to confirm its presence and demonstrate its clinical relevance. The study specifically highlighted that cFLIP overexpression is a hallmark of the ABC-DLBCL subtype, which is notorious for poor patient prognosis. By genetically deleting this protein in a controlled environment, the researchers were able to stop lymphoma development entirely.